An Anti-B7-H4 antibody-drug conjugate for the treatment of breast cancer

Steven R. Leong, Wei-Ching Liang, Yan Wu, Lisa Crocker, Eric Cheng, Deepak Sampath, Rachana Ohri, Helga Raab, Philip E. Hass, Thinh Pham, Ron Firestein, Dongwei Li, Melissa Schutten, Nicola J. Stagg, Annie Ogasawara, Neelima Koppada, Leslie Roth, Simon P. Williams, Byoung-Chul Lee, Cecile ChalouniIvan Peng, Jason DeVoss, Jarrod Tremayne, Paul Polakis, Andrew G. Polson

Research output: Contribution to journalArticleResearchpeer-review

32 Citations (Scopus)

Abstract

B7-H4 has been implicated in cancers of the female reproductive system and investigated for its possible use as a biomarker for cancer, but there are no preclinical studies to demonstrate that B7-H4 is a molecular target for therapeutic intervention of cancer. We provide evidence that the prevalence and expression levels of B7-H4 are high in different subtypes of breast cancer and that only a few normal tissues express B7-H4 on the cell membrane. These profiles of low normal expression and upregulation in cancer provide an opportunity for the use of antibody-drug conjugates (ADCs), cytotoxic drugs chemically linked to antibodies, for the treatment of B7-H4 positive cancers. We have developed an ADC specific to B7-H4 that uses a linker drug consisting of a potent antimitotic, monomethyl auristatin E (MMAE), linked to engineered cysteines (THIOMAB) via a protease labile linker. We will refer to ADCs that use the THIOMAB format as TDCs to help distinguish the format from standard MC-vc-MMAE ADCs that are conjugated to the interchain disulfide bonds. Anti-B7-H4 (h1D11)-MC-vc-PAB-MMAE (h1D11 TDC) produced durable tumor regression in cell line and patient-derived xenograft models of triple-negative breast cancer. It also binds rat B7-H4 with similar affinity to human and allowed us to test for target dependent toxicity in rats. We found that our anti-B7-H4 TDC has toxicity findings similar to untargeted TDC. Our results validate B7-H4 as an ADC target for breast cancer and support the possible use of this TDC in the treatment of B7-H4+ breast cancer.

Original languageEnglish
Pages (from-to)1717-1729
Number of pages13
JournalMolecular Pharmaceutics
Volume12
Issue number6
DOIs
Publication statusPublished - Jun 2015
Externally publishedYes

Keywords

  • antibody drug conjugate
  • B7-H4
  • breast cancer
  • monomethyl auristatin E (MMAE)
  • preclinical validation

Cite this

Leong, S. R., Liang, W-C., Wu, Y., Crocker, L., Cheng, E., Sampath, D., ... Polson, A. G. (2015). An Anti-B7-H4 antibody-drug conjugate for the treatment of breast cancer. Molecular Pharmaceutics, 12(6), 1717-1729. https://doi.org/10.1021/mp5007745
Leong, Steven R. ; Liang, Wei-Ching ; Wu, Yan ; Crocker, Lisa ; Cheng, Eric ; Sampath, Deepak ; Ohri, Rachana ; Raab, Helga ; Hass, Philip E. ; Pham, Thinh ; Firestein, Ron ; Li, Dongwei ; Schutten, Melissa ; Stagg, Nicola J. ; Ogasawara, Annie ; Koppada, Neelima ; Roth, Leslie ; Williams, Simon P. ; Lee, Byoung-Chul ; Chalouni, Cecile ; Peng, Ivan ; DeVoss, Jason ; Tremayne, Jarrod ; Polakis, Paul ; Polson, Andrew G. / An Anti-B7-H4 antibody-drug conjugate for the treatment of breast cancer. In: Molecular Pharmaceutics. 2015 ; Vol. 12, No. 6. pp. 1717-1729.
@article{558a36ee18834f5c8951f3a96bf6aa71,
title = "An Anti-B7-H4 antibody-drug conjugate for the treatment of breast cancer",
abstract = "B7-H4 has been implicated in cancers of the female reproductive system and investigated for its possible use as a biomarker for cancer, but there are no preclinical studies to demonstrate that B7-H4 is a molecular target for therapeutic intervention of cancer. We provide evidence that the prevalence and expression levels of B7-H4 are high in different subtypes of breast cancer and that only a few normal tissues express B7-H4 on the cell membrane. These profiles of low normal expression and upregulation in cancer provide an opportunity for the use of antibody-drug conjugates (ADCs), cytotoxic drugs chemically linked to antibodies, for the treatment of B7-H4 positive cancers. We have developed an ADC specific to B7-H4 that uses a linker drug consisting of a potent antimitotic, monomethyl auristatin E (MMAE), linked to engineered cysteines (THIOMAB) via a protease labile linker. We will refer to ADCs that use the THIOMAB format as TDCs to help distinguish the format from standard MC-vc-MMAE ADCs that are conjugated to the interchain disulfide bonds. Anti-B7-H4 (h1D11)-MC-vc-PAB-MMAE (h1D11 TDC) produced durable tumor regression in cell line and patient-derived xenograft models of triple-negative breast cancer. It also binds rat B7-H4 with similar affinity to human and allowed us to test for target dependent toxicity in rats. We found that our anti-B7-H4 TDC has toxicity findings similar to untargeted TDC. Our results validate B7-H4 as an ADC target for breast cancer and support the possible use of this TDC in the treatment of B7-H4+ breast cancer.",
keywords = "antibody drug conjugate, B7-H4, breast cancer, monomethyl auristatin E (MMAE), preclinical validation",
author = "Leong, {Steven R.} and Wei-Ching Liang and Yan Wu and Lisa Crocker and Eric Cheng and Deepak Sampath and Rachana Ohri and Helga Raab and Hass, {Philip E.} and Thinh Pham and Ron Firestein and Dongwei Li and Melissa Schutten and Stagg, {Nicola J.} and Annie Ogasawara and Neelima Koppada and Leslie Roth and Williams, {Simon P.} and Byoung-Chul Lee and Cecile Chalouni and Ivan Peng and Jason DeVoss and Jarrod Tremayne and Paul Polakis and Polson, {Andrew G.}",
year = "2015",
month = "6",
doi = "10.1021/mp5007745",
language = "English",
volume = "12",
pages = "1717--1729",
journal = "Molecular Pharmaceutics",
issn = "1543-8384",
publisher = "American Chemical Society",
number = "6",

}

Leong, SR, Liang, W-C, Wu, Y, Crocker, L, Cheng, E, Sampath, D, Ohri, R, Raab, H, Hass, PE, Pham, T, Firestein, R, Li, D, Schutten, M, Stagg, NJ, Ogasawara, A, Koppada, N, Roth, L, Williams, SP, Lee, B-C, Chalouni, C, Peng, I, DeVoss, J, Tremayne, J, Polakis, P & Polson, AG 2015, 'An Anti-B7-H4 antibody-drug conjugate for the treatment of breast cancer', Molecular Pharmaceutics, vol. 12, no. 6, pp. 1717-1729. https://doi.org/10.1021/mp5007745

An Anti-B7-H4 antibody-drug conjugate for the treatment of breast cancer. / Leong, Steven R.; Liang, Wei-Ching; Wu, Yan; Crocker, Lisa; Cheng, Eric; Sampath, Deepak; Ohri, Rachana; Raab, Helga; Hass, Philip E.; Pham, Thinh ; Firestein, Ron; Li, Dongwei; Schutten, Melissa; Stagg, Nicola J.; Ogasawara, Annie; Koppada, Neelima; Roth, Leslie; Williams, Simon P.; Lee, Byoung-Chul; Chalouni, Cecile; Peng, Ivan; DeVoss, Jason; Tremayne, Jarrod; Polakis, Paul; Polson, Andrew G.

In: Molecular Pharmaceutics, Vol. 12, No. 6, 06.2015, p. 1717-1729.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - An Anti-B7-H4 antibody-drug conjugate for the treatment of breast cancer

AU - Leong, Steven R.

AU - Liang, Wei-Ching

AU - Wu, Yan

AU - Crocker, Lisa

AU - Cheng, Eric

AU - Sampath, Deepak

AU - Ohri, Rachana

AU - Raab, Helga

AU - Hass, Philip E.

AU - Pham, Thinh

AU - Firestein, Ron

AU - Li, Dongwei

AU - Schutten, Melissa

AU - Stagg, Nicola J.

AU - Ogasawara, Annie

AU - Koppada, Neelima

AU - Roth, Leslie

AU - Williams, Simon P.

AU - Lee, Byoung-Chul

AU - Chalouni, Cecile

AU - Peng, Ivan

AU - DeVoss, Jason

AU - Tremayne, Jarrod

AU - Polakis, Paul

AU - Polson, Andrew G.

PY - 2015/6

Y1 - 2015/6

N2 - B7-H4 has been implicated in cancers of the female reproductive system and investigated for its possible use as a biomarker for cancer, but there are no preclinical studies to demonstrate that B7-H4 is a molecular target for therapeutic intervention of cancer. We provide evidence that the prevalence and expression levels of B7-H4 are high in different subtypes of breast cancer and that only a few normal tissues express B7-H4 on the cell membrane. These profiles of low normal expression and upregulation in cancer provide an opportunity for the use of antibody-drug conjugates (ADCs), cytotoxic drugs chemically linked to antibodies, for the treatment of B7-H4 positive cancers. We have developed an ADC specific to B7-H4 that uses a linker drug consisting of a potent antimitotic, monomethyl auristatin E (MMAE), linked to engineered cysteines (THIOMAB) via a protease labile linker. We will refer to ADCs that use the THIOMAB format as TDCs to help distinguish the format from standard MC-vc-MMAE ADCs that are conjugated to the interchain disulfide bonds. Anti-B7-H4 (h1D11)-MC-vc-PAB-MMAE (h1D11 TDC) produced durable tumor regression in cell line and patient-derived xenograft models of triple-negative breast cancer. It also binds rat B7-H4 with similar affinity to human and allowed us to test for target dependent toxicity in rats. We found that our anti-B7-H4 TDC has toxicity findings similar to untargeted TDC. Our results validate B7-H4 as an ADC target for breast cancer and support the possible use of this TDC in the treatment of B7-H4+ breast cancer.

AB - B7-H4 has been implicated in cancers of the female reproductive system and investigated for its possible use as a biomarker for cancer, but there are no preclinical studies to demonstrate that B7-H4 is a molecular target for therapeutic intervention of cancer. We provide evidence that the prevalence and expression levels of B7-H4 are high in different subtypes of breast cancer and that only a few normal tissues express B7-H4 on the cell membrane. These profiles of low normal expression and upregulation in cancer provide an opportunity for the use of antibody-drug conjugates (ADCs), cytotoxic drugs chemically linked to antibodies, for the treatment of B7-H4 positive cancers. We have developed an ADC specific to B7-H4 that uses a linker drug consisting of a potent antimitotic, monomethyl auristatin E (MMAE), linked to engineered cysteines (THIOMAB) via a protease labile linker. We will refer to ADCs that use the THIOMAB format as TDCs to help distinguish the format from standard MC-vc-MMAE ADCs that are conjugated to the interchain disulfide bonds. Anti-B7-H4 (h1D11)-MC-vc-PAB-MMAE (h1D11 TDC) produced durable tumor regression in cell line and patient-derived xenograft models of triple-negative breast cancer. It also binds rat B7-H4 with similar affinity to human and allowed us to test for target dependent toxicity in rats. We found that our anti-B7-H4 TDC has toxicity findings similar to untargeted TDC. Our results validate B7-H4 as an ADC target for breast cancer and support the possible use of this TDC in the treatment of B7-H4+ breast cancer.

KW - antibody drug conjugate

KW - B7-H4

KW - breast cancer

KW - monomethyl auristatin E (MMAE)

KW - preclinical validation

UR - http://www.scopus.com/inward/record.url?scp=84930673864&partnerID=8YFLogxK

U2 - 10.1021/mp5007745

DO - 10.1021/mp5007745

M3 - Article

C2 - 25853436

AN - SCOPUS:84930673864

VL - 12

SP - 1717

EP - 1729

JO - Molecular Pharmaceutics

JF - Molecular Pharmaceutics

SN - 1543-8384

IS - 6

ER -

Leong SR, Liang W-C, Wu Y, Crocker L, Cheng E, Sampath D et al. An Anti-B7-H4 antibody-drug conjugate for the treatment of breast cancer. Molecular Pharmaceutics. 2015 Jun;12(6):1717-1729. https://doi.org/10.1021/mp5007745